Medigene Expands Platform with Three New Patent Submissions to EPO

Planegg/Martinsried, May 28, 2024 – Medigene AG, an immuno-oncology company specializing in T cell immunotherapies for solid tumors, has filed three new patents with the European Patent Office. These patents highlight Medigene's ongoing efforts to enhance T cell-based treatments for solid tumors.

Interferon-Gamma (IFNγ) Biosensor

The first patent involves Medigene's pioneering Interferon-gamma (IFNγ) Biosensor. This technology facilitates real-time monitoring and quantification of IFNγ release from cytokine-secreting cells. It utilizes a simplified and efficient cytometry detection method, offering a significant improvement over current commercial tools that are often expensive, time-consuming, and susceptible to errors due to their complexity. Additionally, conventional methods typically only allow for endpoint measurements and do not support real-time monitoring over extended periods, a gap that the IFNγ Biosensor aims to fill.

High Precision TCR Tracking: UniTope & TraCR

Medigene has also submitted two patents for its novel T cell receptor (TCR)-specific Antigen-Antibody combination technology, UniTope & TraCR. This technology is designed to uniquely tag the TCR and track its location precisely. This enables accurate evaluation of TCR-guided cell therapies, whether in vitro or in vivo, providing crucial insights into the efficacy and mechanisms of these therapies.

Selwyn Ho, CEO of Medigene, stated, "The patent applications submitted to the European Patent Office highlight our unique scientific and technical approach. These innovative tools enhance our End-to-End (E2E) Platform by integrating new proprietary technologies. They improve reproducibility in measuring safety and efficacy parameters early in the development process, substantially reducing time and cost."

Expanding Patent Portfolio

Medigene continues to expand and strengthen its patent portfolio with new technologies, extending existing patents into additional jurisdictions. The company currently holds over 20 different patent families worldwide, covering applications that protect its sensitive, specific, and safe (3S) TCRs and its exclusive E2E Platform technologies.

About Medigene AG

Medigene AG is an immuno-oncology platform company focused on developing differentiated T cell therapies for solid tumors. Its End-to-End Platform integrates multiple proprietary technologies to create optimal T cell receptors targeting both cancer testis antigens and neoantigens. These TCR-T cells are armored and enhanced to develop best-in-class, differentiated TCR-T therapies. The platform also optimizes the drug product composition for safety, efficacy, and durability. Medigene’s lead TCR-T program, MDG1015, is set for IND filing in Q3 2024 and CTA filing in Q4 2024.

About Medigene’s End-to-End Platform

Medigene’s immunotherapies activate a patient's defense mechanisms by leveraging T cells to combat cancer. The End-to-End Platform includes multiple technologies for TCR generation and optimization, such as Allogeneic-HLA (Allo-HLA) TCR Priming, and product enhancement technologies like PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins. These technologies address the challenges in developing effective, durable, and safe TCR-T therapies. Partnerships with notable companies including BioNTech and Regeneron validate the platform’s assets and technologies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!